Implication of the toll-like receptor 4 pathway in the response to interferon-β in multiple sclerosis

Annals of Neurology

Volumn 70, Issue 4, 2011, Pages 634-645

  Bustamante, Marta F ^a   Fissolo, Nicolás ^a   Río, Jordi ^a   Espejo, Carmen ^a   Costa, Carme ^a   Mansilla, María José ^a   Lizasoain, Ignacio ^b   Moro, María Angeles ^b   Edo, Mari Carmen ^a   Montalban, Xavier ^a   Comabella, Manuel ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; RECOMBINANT BETA INTERFERON; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; IMMUNOLOGIC FACTOR; INTERFERON;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; DRUG EFFECT; GENETICS; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; TREATMENT OUTCOME;

ADULT; COHORT STUDIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON TYPE I; INTERFERON-BETA; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TREATMENT OUTCOME;

EID: 84455168430     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22511     Document Type: Article

References (20)

1. The Interferon b Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294. (Pubitemid 26100751)
3. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
4. Rio J, Nos C, Tintoré M, et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: Implications for clinical trials. Ann Neurol 2002;52:400-406.
5. Comabella M, Lünemann JD, Río J, et al. A type I interferon signature in monocytes is associated with poor response to interferon-b in multiple sclerosis. Brain 2009;132:3353-3365.
6. Takeda K, Akira S. Roles of Toll-like receptors in innate immune responses. Genes Cells 2001;6:733-742. (Pubitemid 32894068)
7. Uematsu S, Akira S. Toll-like receptors and innate immunity. J Mol Med 2006;84:712-725. (Pubitemid 44328063)
8. Akira S. TLR signaling. Curr Top Microbiol Immunol 2006;311:1-16. (Pubitemid 47413193)
9. Yang QW, Li JC, Lu FL, et al. Upregulated expression of toll-like receptor 4 in monocytes correlates with severity of acute cerebral infarction. J Cereb Blood Flow Metab 2008;28:1588-1596.
10. Devaraj S, Jialal I, Yun JM, Bremer A. Demonstration of increased toll-like receptor 2 and toll-like receptor 4 expression in monocytes of type 1 diabetes mellitus patients with microvascular complications. Metabolism 2011;60:256-259.
11. Rothlin CV, Ghosh S, Zuniga EI, et al. MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 2007;131:1124-1136. (Pubitemid 350235020)
12. Rio J, Nos C, Tintoré M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352. (Pubitemid 43202488)
13. Byun E, Caillier SJ, Montalban X, et al. Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. Arch Neurol 2008;65:337-344. (Pubitemid 351398518)
14. Kerfoot SM, Long EM, Hickey MJ, et al. TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol 2004;173:7070-7077. (Pubitemid 39541097)
15. Marta M, Andersson A, Isaksson M, et al. Unexpected regulatory roles of TLR4 and TLR9 in experimental autoimmune encephalomyelitis. Eur J Immunol 2008;38:565-575.
16. Axtell RC, de Jong BA, Boniface K, et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med 2010;16:406-412.
17. Wesche H, Gao X, Li X, et al. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 1999;274:19403-19410.
18. Kobayashi K, Hernandez LD, Galá n JE, et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002;110: 191-202. (Pubitemid 34876547)
19. An H, Hou J, Zhou J, et al. Phosphatase SHP-1 promotes TLRand RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat Immunol 2008;9:542-550. (Pubitemid 351560523)
20. O'Neill LA. "Fine tuning" TLR signaling. Nat Immunol 2008;9: 459-461.